Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Sixty chronic hemodialysis patients were randomly assigned to receive fenofibrate 100 mg
(group 1, n = 30) or simvastatin 20 mg (group 2, n = 30) three times/week after their
dialysis session. The safety and efficacy of drugs on lipid profile, oxidized low density
lipoproteins (ox-LDL), glutathione peroxidase (GSH-Px) and C-reactive protein (CRP) were
compared before and after 16-week treatment.